Data may be delayed — last successful sync 2026-09-26 (19 days ago). Figures reflect the most recent completed ingest.
Company profile
Avalon GloboCare Corp.
NASDAQ: ALBT · Healthcare · Biotechnology
#1162 of 1,417 Healthcare companies by revenuebottom-decile growth
EA Score
35DFH 32DQ 51GM 19SS 26
v0.1 · 65/100 weight · provisional
↑ disclosure history, growth stability · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
-$349.8k
Rev growth YoY (TTM)
-125.6%
Net income (FY)
-$18.3M
Employees
2
as of 2026-09-25
Market cap
$923.2k
as of 2026-09-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$18.3M-$18.3M2025
Operating income-$7.6M-$7.6M2025
Total assets$23.4M$23.4M2025
Liabilities$14.2M$14.2M2025
Equity$9.2M$9.2M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2023
By product
Corporate Other Member100%
By geography
Not disclosed.
The read
What is Avalon GloboCare Corp.’s revenue?
Avalon GloboCare Corp. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Decoy Therapeutics Inc.30DLifeline Biotechnologies, Inc.——Odyssey Health, Inc.21DMulticorp International, Inc.——Hepion Pharmaceuticals, Inc.24DGenix Pharmaceuticals Corporation——Neighbors
Monmouth →Key facts
CEOMeng Li
SectorHealthcare
IndustryBiotechnology
HeadquartersFreehold, NJ
ExchangeNASDAQ: ALBT
Employees2
IPO date2018-03-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.